Shares of Neurotrope Inc (NASDAQ:NTRP) have earned an average broker rating score of 3.00 (Hold) from the two analysts that cover the stock, Zacks Investment Research reports. Two equities research analysts have rated the stock with a hold recommendation. Neurotrope’s rating score has declined by 200% in the last three months as a result of a number of analysts’ upgrades and downgrades.

Brokers have set a 12 month consensus target price of $1.00 for the company and are expecting that the company will post ($0.32) EPS for the current quarter, according to Zacks. Zacks has also assigned Neurotrope an industry rank of 104 out of 255 based on the ratings given to related companies.

A number of research firms have weighed in on NTRP. ValuEngine raised shares of Neurotrope from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Zacks Investment Research cut shares of Neurotrope from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Janney Montgomery Scott cut shares of Neurotrope from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $13.00 to $1.00 in a research report on Wednesday, September 11th. Finally, Maxim Group cut shares of Neurotrope from a “buy” rating to a “hold” rating in a research report on Monday, September 9th.

Hedge funds have recently modified their holdings of the company. Morgan Stanley lifted its position in shares of Neurotrope by 46.7% during the second quarter. Morgan Stanley now owns 20,402 shares of the company’s stock worth $164,000 after purchasing an additional 6,490 shares during the last quarter. BlackRock Inc. lifted its position in shares of Neurotrope by 144.3% during the second quarter. BlackRock Inc. now owns 60,041 shares of the company’s stock worth $482,000 after purchasing an additional 35,464 shares during the last quarter. NorthRock Partners LLC lifted its position in shares of Neurotrope by 45.5% during the second quarter. NorthRock Partners LLC now owns 104,000 shares of the company’s stock worth $834,000 after purchasing an additional 32,500 shares during the last quarter. Cannell Peter B & Co. Inc. lifted its position in shares of Neurotrope by 7.5% during the second quarter. Cannell Peter B & Co. Inc. now owns 229,481 shares of the company’s stock worth $1,840,000 after purchasing an additional 16,100 shares during the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of Neurotrope by 21.7% during the second quarter. Vanguard Group Inc. now owns 266,735 shares of the company’s stock worth $2,139,000 after purchasing an additional 47,609 shares during the last quarter. 14.98% of the stock is currently owned by institutional investors and hedge funds.

NASDAQ:NTRP opened at $0.71 on Tuesday. The firm has a 50-day moving average of $0.70 and a two-hundred day moving average of $4.64. The stock has a market cap of $9.04 million, a P/E ratio of -0.52 and a beta of 2.07. Neurotrope has a 1-year low of $0.63 and a 1-year high of $8.40.

Neurotrope Company Profile

Neurotrope, Inc, a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. Its lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. The company also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases.

Featured Article: Sell-Side Analysts

Get a free copy of the Zacks research report on Neurotrope (NTRP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Neurotrope Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurotrope and related companies with MarketBeat.com's FREE daily email newsletter.